Blinded sample size re-estimation in crossover bioequivalence trials.
In drug development, bioequivalence studies are used to indirectly demonstrate clinical equivalence of a test formulation and a reference formulation of a specific drug by establishing their equivalence in bioavailability. These studies are typically run as crossover studies. In the planning phase of such trials, investigators and sponsors are often faced with a high variability in the coefficients of variation of the typical pharmacokinetic endpoints such as the area under the concentration curve or the maximum plasma concentration. Adaptive designs have recently been considered to deal with this uncertainty by adjusting the sample size based on the accumulating data. Because regulators generally favor sample size re-estimation procedures that maintain the blinding of the treatment allocations throughout the trial, we propose in this paper a blinded sample size re-estimation strategy and investigate its error rates. We show that the procedure, although blinded, can lead to some inflation of the type I error rate. In the context of an example, we demonstrate how this inflation of the significance level can be adjusted for to achieve control of the type I error rate at a pre-specified level. Furthermore, some refinements of the re-estimation procedure are proposed to improve the power properties, in particular in scenarios with small sample sizes.
Institute of Medical Biometry and Informatics, University of Heidelberg, Im Neuenheimer Feld 305, D-69115 Heidelberg, Germany.
Daniel
D
Golkowski
Tim
T
Friede
Meinhard
M
Kieser
D002986:Clinical Trials as Topic / Q000379:methods*; D018592:Cross-Over Studies; D015195:Drug Design; D006801:Humans; D010599:Pharmacokinetics; D010865:Pilot Projects; D012107:Research Design; D018401:Sample Size; D013810:Therapeutic Equivalency
bioequivalence; crossover trials; internal pilot study; sample size re-estimation